KLK3 and ocular melanoma: Furthermore, in an analysis excluding those who did not change the systematic treatment at the time of SABR, there was a trend toward improved PSA-PFS (19.8 vs. 4.2 months, p = 0.05), DMFS (23.6 vs. 8.9 months, p = 0.007), and TTNI (20.3 vs. 8.8 months, p = 0.079) in OM-CRPC who underwent SABR in addition to change in systemic therapy compared with OM-CRPC who underwent change in systemic therapy alone and no SABR, indicating that the combination of SABR and change in systemic therapy for OM-CRPC has the potential to improve oncologic outcome [14].